Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to Ritonavir-boosted Indinavir and Efavirenz

被引:25
作者
Boyd, Mark A.
Carr, Andrew
Ruxrungtham, Kiat
Srasuebkul, Preeyaporn
Bien, Darl
Law, Matthew
Wangsuphachart, Somjai
Krisanachinda, Anchali
Lerdlum, Sakalaya
Lange, Joep M. A.
Phanuphak, Praphan
Cooper, David A.
Reiss, Peter
机构
[1] Flinders Univ S Australia, Med Ctr, Dept Microbiol & Infect Dis, Bedford Pk, SA 5042, Australia
[2] HIV Netherlands Australia Thialand Res Collaborat, Thai Red Cross AIDS Res Ctr, Bangkok, Thailand
[3] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand
[4] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[5] St Vincents Hosp, Sydney, NSW 2010, Australia
[6] Univ Denver, Denver, CO USA
[7] Acad Med Ctr, Int Antiviral Therapy Evaluat Ctr, Dept Infect Dis Trop Med & AIDS, Amsterdam, Netherlands
关键词
D O I
10.1086/505709
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. Body composition changes complicate antiretroviral therapy. Improvements in lipoatrophy after a switch in nucleoside reverse -transcriptase inhibitors (NRTIs) have been demonstrated. We investigated 60 patients switching from failed NRTIs to ritonavir-boosted indinavir and efavirenz. Methods. Body composition (assessed by dual-energy x-ray absorptiometry scan and by single-slice computed tomography of the abdomen through the level of the fourth lumbar vertebra [L4] and the mid-right thigh) and fasted metabolics were measured at the baseline time-point at switch and at weeks 48 and 96 thereafter. Mitochondrial DNA and RNA were extracted from right-thigh subcutaneous fat and peripheral-blood mononuclear cells (PBMCs) at weeks 0 and 48. The primary end point was the change in mean limb fat over 48 weeks. Results. At week 96, we observed increases in mean (standard deviation [SD]) limb fat (+620 [974] g; P =.003), L4 subcutaneous adipose tissue (+20 [35] cm(2); P < .001), mid-thigh subcutaneous adipose tissue (+5 [10] cm(2); P < .001), and L4 visceral adipose tissue (+11 [34] cm(2); P =.01), but we also observed reduced lean limb mass (-831 [1100] g; P = .3). Mean (SD) mtDNA content in subcutaneous fat and in PBMCs increased (+109 [274] and +45 [100] copies/cell, respectively). Improved virological control or immune recovery did not explain the results. Triglyceride, total cholesterol, estimated low-density lipoprotein cholesterol, ratio of total cholesterol to high-density lipoprotein cholesterol, and blood glucose levels deteriorated (i.e., had increased by 206%, 67%, 58%, 19%, and 6%, respectively, at week 96). Conclusions. This regimen was associated with statistically significant but clinically modest increases in peripheral fat, visceral fat, and mitochondrial nucleic acid content. A predominantly adverse metabolic profile developed.
引用
收藏
页码:642 / 650
页数:9
相关论文
共 34 条
[1]
Banas B, 2004, EUR J MED RES, V9, P371
[2]
RAPID AND SIMPLE METHOD FOR PURIFICATION OF NUCLEIC-ACIDS [J].
BOOM, R ;
SOL, CJA ;
SALIMANS, MMM ;
JANSEN, CL ;
WERTHEIMVANDILLEN, PME ;
VANDERNOORDAA, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (03) :495-503
[3]
Indinavir/ritonavir 800/100mg bid and efavirenz 600mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009 [J].
Boyd, MA ;
Siangphoe, U ;
Ruxrungtham, K ;
Duncombe, CJ ;
Stek, M ;
Lange, JMA ;
Cooper, DA ;
Phanuphak, P .
HIV MEDICINE, 2005, 6 (06) :410-420
[4]
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[5]
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy - A randomized trial [J].
Carr, A ;
Workman, C ;
Smith, DE ;
Hoy, J ;
Hudson, J ;
Doong, N ;
Martin, A ;
Amin, J ;
Freund, J ;
Law, M ;
Cooper, DA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :207-215
[6]
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[7]
Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy [J].
Casula, M ;
Weverling, GJ ;
Wit, FW ;
Timmermans, EC ;
Stek, M ;
Lange, JM ;
Reiss, P .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (10) :1794-1800
[8]
Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI [10.1097/00126334-200207010-00002, 10.1097/01.QAI.0000017962.22053.0E]
[9]
Cossarizza A, 2003, ANTIVIR THER, V8, P315
[10]
Côte HCF, 2005, ANTIVIR THER, V10, pM3